Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLight: AZD4512 monotherapy in relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia
CTR20261354Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AZD4512 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by AstraZeneca. Started Nov 2025; status: active.
02
Drugs
AZD4512
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20261354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261354.